Learn more about the benefits of early sodium-glucose cotransporter 2 inhibitor initiation for heart failure patients, both in the acute and chronic settings, in improving CV and hospitalization outcomes and mitigating the damage of upstream cardio-renal-metabolic (CRM) risk factors.

Learn more about cardio-renal-metabolic (CRM) diseases, including type 2 diabetes mellitus (T2D), diabetic kidney disease (DKD) and heart failure (HF), and the effectiveness of empagliflozin, a sodium-glucose cotransporter 2 inhibitor (SGLT2i), in mitigating cardiovascular and mortality risks and preserving kidney function.